Table 4 New signal strength at the PT level for Furosemide, torsemide, and bumetanide
Drug | Preferred Term (PT) | N | ROR (95% CI) | p |
|---|---|---|---|---|
Furosemide | Vitamin b1 deficiency | 65 | 156.59(119.63, 204.97) | <0.01 |
Gastrointestinal tract mucosal pigmentation | 38 | 145.61(102.63, 206.59) | <0.01 | |
Wernicke’s encephalopathy | 41 | 64.48(46.82, 88.81) | <0.01 | |
Torsemide | Palisaded neutrophilic granulomatous dermatitis | 6 | 1592.54(645.57, 3928.58) | <0.01 |
Systemic infection | 28 | 108.04(74.3, 157.1) | <0.01 | |
Respiratory tract haemorrhage | 3 | 31.55(10.14, 98.15) | <0.01 | |
Coarctation of the aorta | 5 | 31.39(13.03, 75.61) | <0.01 | |
Haematochezia | 45 | 5.52(4.11, 7.39) | <0.01 | |
Haematemesis | 19 | 4.81(3.06, 7.54) | <0.01 | |
Haematuria | 18 | 3.34(2.1, 5.31) | <0.01 | |
Pemphigoid | 15 | 14.63(8.81, 24.3) | <0.01 | |
Toxic epidermal necrolysis (TEN) | 9 | 3.97(2.07, 7.64) | <0.01 | |
Prothrombin time prolonged | 7 | 7.01(3.34, 14.72) | <0.01 | |
Bumetanide | Blood ketone body increased | 3 | 109.76(35.28, 341.5) | <0.01 |
Metabolic encephalopathy | 4 | 34.77(13.03, 92.8) | <0.01 | |
Lip swelling | 6 | 4.73(2.12, 10.54) | <0.01 | |
Stevens-Johnson syndrome (SJS) | 4 | 4.62(1.73, 12.32) | <0.01 | |
Pemphigoid | 3 | 11.5(3.71, 35.71) | <0.01 |